• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background

    Achondrogenesis Companies

    ID: MRFR/MED/3247-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Achondrogenesis is a rare genetic disorder characterized by a lack of cartilage formation during fetal development, resulting in severe skeletal abnormalities. Due to the rarity and severity of this condition, there may not be specific companies exclusively focused on achondrogenesis. Instead, research and medical efforts related to rare genetic disorders often involve collaborations among academic institutions, medical centers, and pharmaceutical companies. These entities may contribute to the understanding of genetic disorders, including achondrogenesis, and the development of potential therapeutic interventions.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Achondrogenesis Market

    Achondrogenesis Market

     


    Latest Achondrogenesis Companies Updates:


    BioMarin Pharmaceutical Inc Develops Vosoritide, a medication approved for the treatment of Achondroplasia and currently being investigated for its potential in Achondrogenesis.


    Horizon Therapeutics plc Develops pegvisomant, a growth hormone receptor antagonist used in various growth disorders, including Achondrogenesis.


    Acceleron Pharma Collaborates with BioMarin on the development of Vosoritide.


    List of Achondrogenesis Key companies in the market:



    • Cook

    • Thermo Fisher Scientific

    • CooperSurgical Inc.

    • Illumina, Inc.

    • Siemens AG

    • FUJIFILM Holdings Corporation

    • Koninklijke

    • Philips N.V

    • Stryker,

    • Toshiba Corporation

    • Invivoscribe

    • Abbott Molecular Inc.

    • INVITROGEN CORPORATION

    • Roche Molecular Systems, Inc.